Lots of interesting abstracts and cases were submitted for TCTAP 2024. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-025
Annual Vascular and Bleeding Outcomes in East Asian Poststenting Patients With Acute Coronary Syndrome: The BRIC-ACS II Trial
By Dandan Li, Yani Yu, Yun-Dai Chen
Presenter
Yani Yu
Authors
Dandan Li1, Yani Yu1, Yun-Dai Chen1
Affiliation
Chinese People's Liberation Army General Hospital, China1
View Study Report
TCTAP A-025
Complication Management
Annual Vascular and Bleeding Outcomes in East Asian Poststenting Patients With Acute Coronary Syndrome: The BRIC-ACS II Trial
Dandan Li1, Yani Yu1, Yun-Dai Chen1
Chinese People's Liberation Army General Hospital, China1
Background
Aims: We aim to determine the incidence of events in the ‘real-world’ acute coronary syndrome Chinese patients over 1-year after percutaneous coronary intervention.
Methods
From November 2017 till April 2020, we enrolled post-stenting acute coronary syndromepatients (n=5515) from 30 hospitals with the strict 1-year follow-up (n=5150).
Results
Only 153(3.0%) patients developed MACE (acomposite of all-cause death, myocardial infarction, ischemic stroke, or urgentcoronary revascularization). The cumulative incidence of annual bleeding (BARC≥2) was 5.8% (298/5150).The BARC≥2 bleeding was higher 298 (5.8%) and was not associated withworsened MACE (P =0.52). Patients treated with ticagrelor (n=1620, 6.0%) had asignificantly increased risk of bleeding than those treated withclopidogrel (n=2331; 4.1%) (HR=1.486;95% CI:1.12-1.97; P=0.006), but similar risk of vascular MACE (2.7% vs 2.8%;HR= 0.94; 95% CI:0.64-1.38; P=0.747).The factors independently associated withthe comprehensive risk of BARC≥2 bleeding and MACE,including female gender, renal insufficiency, peptic ulcer, atrialfibrillation, continuous use of ticagrelor and non-continuous DAPT. Thediscrimination of the nomogram model was further tested by the ROC curve (AUCvalue:0.610 (95% CI, 0.577-0.642)).
Conclusion
The annual incidence of BARC≥2 bleeding in ACS patientstreated with PCI in China was higher (5.8%) than MACE (3.0%). DAPT withticagrelor increased the bleeding rates with no trend towards MACE reduction.